MARKET

CDTX

CDTX

Cidara
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.400
-0.030
-1.23%
Opening 12:18 02/25 EST
OPEN
2.430
PREV CLOSE
2.430
HIGH
2.460
LOW
2.340
VOLUME
489.81K
TURNOVER
--
52 WEEK HIGH
4.450
52 WEEK LOW
1.300
MARKET CAP
105.46M
P/E (TTM)
-1.4535
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Press Release: UTILITY Therapeutics Joins Antimicrobials Working Group
Dow Jones · 02/17 15:04
Cidara Therapeutics Announces New Data For Rezafungin At The 21st ICHS Symposium
Cidara Therapeutics Announces New Data for Rezafungin at the 21st ICHS Symposium SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing long-acting
Benzinga · 02/17 13:04
Cidara Therapeutics Announces New Data for Rezafungin at the 21st ICHS Symposium
SAN DIEGO, Feb 17, 2021 (GLOBE NEWSWIRE via COMTEX) -- SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology...
GlobeNewswire · 02/17 13:00
Cidara Therapeutics to Present New Data for Rezafungin and Influenza AVCs at the 21st ICHS Symposium
SAN DIEGO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today anno...
GlobeNewswire · 02/11 13:00
Candidiasis Therapeutics Market 2020 New Opportunities, Top Trends, Rising Demand, Emerging Growth, Business Development and Regional Analysis 2025
Comserve · 02/05 11:14
Acute Vulvovaginal Candidiasis Treatment Industry Analysis 2021 Trends, Size, Growth Insight, Share, Competitive Analysis, Statistics, Regional, Market Demand, Development Status, Opportunities Forecast to 2025
Feb 02, 2021 (The Expresswire) -- Global "Acute Vulvovaginal Candidiasis Treatment Market" report is a comprehensive research that provides information...
The Express Wire · 02/02 07:26
Cidara Therapeutics Inc Announces Orphan Drug Designation Granted To Rezafungin In EU For Treatment Of Invasive Candidiasis
-Reuters
Reuters · 01/26 13:14
8-K: Cidara Therapeutics, Inc.
(EDGAR Online via COMTEX) -- 0001610618false00016106182021-01-222021-01-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 01/25 14:47
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CDTX. Analyze the recent business situations of Cidara through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CDTX stock price target is 6.40 with a high estimate of 10.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 105
Institutional Holdings: 28.64M
% Owned: 65.18%
Shares Outstanding: 43.94M
TypeInstitutionsShares
Increased
22
926.16K
New
19
-2.01M
Decreased
17
1.40M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.63%
Pharmaceuticals & Medical Research
-0.66%
Key Executives
Chairman/Independent Director
Daniel Burgess
President/Chief Executive Officer/Director
Jeffrey Stein
Chief Financial Officer
James Levine
Chief Operating Officer
Paul Daruwala
General Counsel/Secretary
Jessica Oien
Other
Neil Abdollahian
Other
Taylor Sandison
Director
Canale-Theakston ..
Director
Bonnie Bassler
Independent Director
Timothy Franson
Independent Director
David Gollaher
Independent Director
Chrysa Mineo
Independent Director
Theodore Schroeder
  • Dividends
  • Splits
  • Insider Activity
No Data
About CDTX
Cidara Therapeutics Inc., is a clinical-stage biotechnology company focused on developing new anti-infectives. The Company’s lead product candidate is rezafungin acetate, which is a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. The Company is also leveraging its novel Cloudbreak platform to develop antibody-drug conjugates for the treatment of serious viral and Gram-negative bacterial infections. Cloudbreak is the immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens.

Webull offers kinds of Cidara Therapeutics Inc stock information, including NASDAQ:CDTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CDTX stock methods without spending real money on the virtual paper trading platform.